B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Bone Marrow Transplantation

• Publication date

  2017-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bmt.2017.73PMID 28481353PMCID PMC5687506
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.

  2016cited by this paper
• Biomarker Panel for Chronic Graft-Versus-Host Disease.

  2016cited by this paper
• APRIL levels are associated with disease activity in human chronic graft-versus-host disease

  2016cited by this paper
• Identification and validation of biomarkers associated with acute and chronic graft versus host disease

  2015cited by this paper
• Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.

  2015cited by this paper
• This information is current as Cytokines in Graft-versus-Host Disease

  2015cited by this paper
• Aberrant B-cell homeostasis in chronic GVHD.

  2015cited by this paper
• Brief Report: Responses to Rituximab Suggest B Cell–Independent Inflammation in Cutaneous Systemic Lupus Erythematosus

  2015cited by this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

  2015cited by this paper
• Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

  2014cited by this paper
• Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.

  2014cited by this paper
• Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia

  2014cited by this paper
• CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome.

  2013cited by this paper
• Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation

  2013cited by this paper
• The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation.

  2012cited by this paper
• B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.

  2012cited by this paper
• Advances in graft-versus-host disease biology and therapy

  2012cited by this paper
• Soluble BAFF Levels Inversely Correlate with Peripheral B Cell Numbers and the Expression of BAFF Receptors

  2012cited by this paper
• Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis.

  2011cited by this paper
• Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD.

  2011cited by this paper
• Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.

  2011cited by this paper
• Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.

  2011cited by this paper
• Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.

  2009cited by this paper
• Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.

  2008cited by this paper
• Summarizing differences in cumulative incidence functions

  2008cited by this paper
• High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease

  2007cited by this paper
• B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels

  2005cited by this paper
• 2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: preface to the series.

  2005cited by this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

  2005cited by this paper
• National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

  2005cited by this paper
• Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation.

  2005cited by this paper
• Chronic graft-versus-host disease: a prospective cohort study.

  2003cited by this paper
• Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study.

  2003cited by this paper
• Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

  2002cited by this paper
• Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling

  2001cited by this paper
• Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus1

  2001cited by this paper
• 1994 Consensus Conference on Acute GVHD Grading.

  1995cited by this paper
• The analysis of failure times in the presence of competing risks.

  1978cited by this paper

• Immune Monitoring after Cell Therapy and Hematopoietic Cell Transplantation: Guidelines by the ISCT Stem Cell Engineering Committee

  2025cites this paper
• Utilization of Clinical Data and Evaluation of Biomarkers in the Investigation of Graft-Versus-Host Disease Outcomes.

  2025cites this paper
• Recent advances and research progress regarding monoclonal antibodies for chronic graft-versus-host disease

  2024cites this paper
• Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants

  2024cites this paper
• Recent Advances and Research Progress in Biomarkers for Chronic Graft Versus Host Disease.

  2023cites this paper
• Chronic graft-versus-host disease is characterized by high levels and distinctive tissue-of-origin patterns of cell-free DNA

  2023cites this paper
• BAFF antagonism via the BAFF receptor 3 binding site attenuates BAFF 60-mer-induced classical NF-κB signaling and metabolic reprogramming of B cells.

  2022cites this paper
• Use of the NIH consensus criteria in cellular and soluble biomarker research in chronic graft-versus-host disease: A systematic review

  2022cites this paper
• Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan

  2022influential citation
• BAFF Promotes Heightened BCR Responsiveness and Manifestations of Chronic GVHD after Allogeneic Stem Cell Transplantation.

  2021cites this paper
• Von Willebrand Factor, Factor VIII, and Other Acute Phase Reactants as Biomarkers of Inflammation and Endothelial Dysfunction in Chronic Graft-Versus-Host Disease

  2021cites this paper
• B regulatory cells and monocyte subpopulations in patients with chronic graft-vs-host disease

  2021cites this paper
• Methods to assess disease activity and severity in cutaneous chronic graft-versus-host disease: a critical literature review.

  2021cites this paper
• Aberrant B cells, autoimmunity and the benefit of targeting B cells in chronic graft-versus-host disease.

  2020cites this paper
• Biomarkers for Allogeneic HCT Outcomes

  2020cites this paper
• Refractory autoimmune haemolytic anaemia following allogenic haematopoietic stem cell transplantation: successful treatment of rituximab

  2019cites this paper
• Summary and Outlook on the Future Challenges of Allogeneic HSCT

  2019cites this paper
• Double-Negative T Cell Levels Correlate with Chronic Graft-versus-Host Disease Severity.

  2019cites this paper
• T Cell– and B Cell–Mediated Pathology in Chronic Graft-Versus-Host Disease

  2019cites this paper
• The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease

  2018influential citation
• Biomarkers for posttransplantation outcomes.

  2018cites this paper
• Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients.

  2018cites this paper
• Developing role of B cells in the pathogenesis and treatment of chronic GVHD

  2018cites this paper
• Clinical Proteomics for Post‐Hematopoeitic Stem Cell Transplantation Outcomes

  2018cites this paper
• Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.

  2016cites this paper